Table 2.
Comparison of patient characteristics between diarrhea and nondiarrhea groups
| Diarrhea (n = 8) | Nondiarrhea (n = 13) | p value | |
|---|---|---|---|
| Age, years† | 73 (69–84) | 73 (69–79) | 0.913 |
| Gender (male/female) | 3/5 | 11/2 | 0.056 |
| BMI, kg/m2† | 26.0 (22.4–28.2) | 24.2 (20.6–27.0) | 0.515 |
| Etiology (HBV/HCV/NBNC/alcohol) | 1/5/2/0 | 1/7/5/0 | 0.830 |
| CPS (5/6) | 2/6 | 7/6 | 0.367 |
| BCLC stage (B/C) | 6/2 | 9/4 | 1.000 |
| Prior TKI use (yes/no) | 2/6 | 0/13 | 0.133 |
| RDI for 6 weeks, %† | 88.5 (62.4–100) | 67.4 (42.8–86.5) | 0.165 |
| mRECIST (SD/PR) | 7/1 | 9/4 | 0.606 |
| DM (yes/no) | 3/5 | 4/9 | 1.000 |
| PPI (yes/no) | 5/3 | 3/10 | 0.164 |
| Pre/probiotics (yes/no) | 1/7 | 0/13 | 0.381 |
| HFS (yes/no) | 5/3 | 4/9 | 0.203 |
| Hypertension (yes/no) | 6/2 | 11/2 | 0.618 |
| Hypothyroidism (yes/no) | 4/4 | 5/8 | 0.673 |
| Urine protein (yes/no) | 4/4 | 10/3 | 0.346 |
BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-B non-C; BCLC stage, Barcelona Clinical Liver Cancer stage; TKI, tyrosine kinase inhibitor; RDI, relative dose intensity; mRECIST, modified Response Evaluation Criteria in Solid Tumors; SD, stable disease; PR, partial response; PPI, proton pump inhibitor; HFS, hand-foot syndrome.
†
Values are expressed as median (interquartile range).